Aktis Oncology Aims to Raise $200 Million in IPO with $860 Million Valuation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: renaissancecapital
- IPO Plans: Aktis Oncology plans to raise $200 million by offering 11.8 million shares, which would give the company an $860 million market cap at the midpoint of the proposed price range, indicating strong market interest in its targeted radiopharmaceuticals.
- Clinical Progress: The ongoing multi-site US Phase 1b trial for Ac-AKY-1189, targeting Nectin-4-expressing cancers, has enrolled about 150 patients, with preliminary results expected in Q1 2027, potentially driving further funding and market validation.
- Pipeline Expansion: Aktis Oncology's pipeline includes Ac-AKY-2519 targeting B7-H3-expressing tumors, with an IND filing planned for 2026, which will enhance its treatment options and competitive positioning in the oncology market.
- Facility Investment: The company is investing in an internal cGMP facility set to be operational in 2026, aimed at increasing production capacity and ensuring a stable supply chain for its radiopharmaceuticals, supporting future business growth.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
